Shares of Fresenius SE & Co KGaA (FRA:FRE) have been given a consensus rating of “Buy” by the eighteen brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is €77.98 ($96.27).

FRE has been the topic of a number of recent analyst reports. Citigroup set a €83.00 ($102.47) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, October 19th. Goldman Sachs Group set a €78.00 ($96.30) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, October 31st. Barclays set a €81.00 ($100.00) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, February 2nd. Warburg Research set a €80.00 ($98.77) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, December 21st. Finally, Bank of America set a €75.00 ($92.59) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, November 6th.

Fresenius SE & Co KGaA (FRA:FRE) traded down €0.78 ($0.96) during trading hours on Friday, reaching €62.64 ($77.33). The company’s stock had a trading volume of 1,630 shares. The company has a market capitalization of $34,480.00 and a PE ratio of 19.95. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($74.27) and a twelve month high of €80.00 ($98.77).

COPYRIGHT VIOLATION WARNING: “Fresenius SE & Co KGaA (FRE) Receives €77.64 Average Price Target from Brokerages” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/13/fresenius-se-77-64-average-price-target-from-brokerages.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.